Giant Cell Arteritis
·MeSH: Arteritis
Prevalence
30.0 / 100K
4 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| tofidence | BIOGEN INC. (BIIB) |
Phase 3(2)
Phase 4(1)
| Drug | Company |
|---|---|
| secukinumab s.c | Novartis AG (NVS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Giant Cell Arteritis?
BioSniper tracks 4 drugs in development for Giant Cell Arteritis across 2 companies.
How many clinical trials target Giant Cell Arteritis?
There are 2 clinical trials targeting Giant Cell Arteritis tracked by BioSniper.
What is the prevalence of Giant Cell Arteritis?
The estimated prevalence of Giant Cell Arteritis is approximately 30.0 per 100,000 population.
Deep-dive into Giant Cell Arteritis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis